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Background: Many individual proteins have been associated with cardiovascular (CV) risk, but studies rarely considered more than a few proteins 
simultaneously to identify which proteins best predict risk.
Methods: We performed a nested case-control study of 273 cases (death/MI during 2.5 yrs follow up) and 273 age, sex and race-matched event-
free controls from among 2023 consecutive patients with suspected coronary disease in the MURDOCK CV study. Plasma levels of 54 previously-
reported biomarkers of CV risk were determined in a core laboratory. Penalized logistic regression models considering all proteins simultaneously 
were fit using the Elastic Net to identify proteins independently associated with death/MI based on 500 bootstrapped samples. We created 3 
models: proteins alone (Model 1); proteins in a model constrained to retain clinical predictors (Model 2); all proteins and clinical variables 
available for selection (Model 3). Inclusion in ≥85% of bootstrapped samples indicated strong evidence of association.
Results: The Table shows proteins and clinical variables with strong association with death/MI and corresponding ORs. Among proteins not 
selected were hsCRP, TNF-_, MCP-1, LpPLA2 (inflammation); troponin I (necrosis); and PAPP-A (plaque instability).
Conclusions: Simultaneous consideration of the association of multiple putative protein biomarkers of CV risk with clinical outcomes may be 
useful to identify the most relevant panel of biomarkers for clinical risk assessment. 
Table. Biomarkers and Clinical Characteristics Strongly Associated with Death or MI
Model 1 Model 2 Model 3
% of 500 bootstrapped 
samples selected
Odds Ratio
% of 500 bootstrapped 
samples selected
Odds Ratio
% of 500 bootstrapped 
samples selected
Odds Ratio
ICAM-1 87.4 1.83 80.2 -- 88.4 1.79
MMP-3 88.4 1.23 74.7 -- 89.2 1.19
sCD40L 91.6 1.16 90.0 1.15 97.4 1.20
NT-proBNP 99.8 1.21 62.3 -- 91.0 1.10
IL-6 94.2 1.22 78.6 -- 93.2 1.19
IGFBP-2 99.8 1.30 82.2 -- 97.6 1.17
Age (per 5 years) -- -- 100 1.26 94.8 1.26
Red cell distribution 
width (RDW)
-- -- 100 1.19 97.6 1.23
NYHA Class -- -- 100 1.17 85.2 1.12
Baseline hemoglobin -- -- 100 0.91 86.2 0.91
Diabetes -- -- 100 1.60 85.6 1.53
Candidate proteins not selected: SAA, CRP, VCAM-1, thrombomodulin, ICAM-3, E-selectin, P-selectin, LBP, MMP-1, MMP-9, TIMP-1, bFGF, VEGF, CKMB, 
myoglobin, troponin I, MCP-1, TNF-_, IL-1b, IL-2, IL-4, IL-10, MCSF, GCSF, IL-1a, IL-18, OPGN, Apo A1, Apo B, Apo E, PDGF AA, PDGF AB/BB, RANTES, 
MPO, Total PAI-1, TNF`, GH, fibrinogen, PAPP-A, vWF, tPA, D-Dimer, GDF-15, PLAC, CAM
Candidate clinical variables: sex, Charlson comorbidity index, smoking status, presence of chest pain, weight, atrial fibrillation, left bundle branch 
block, blood pressure, heart rate, ejection fraction, white blood cell count, creatinine, BUN, Duke coronary artery disease index, corrected QT interval
*Odds ratios were calculated using logistic regression models of the variable selected from the Elastic Net.
